Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Source: View publication →
In patients with atrial fibrillation undergoing successful PCI, a dual antithrombotic regimen of edoxaban plus a P2Y12 inhibitor was non-inferior for bleeding risk compared to standard VKA-based triple therapy, without a significant increase in ischemic events.
Key Findings
Study Design
Study Limitations
Clinical Significance
ENTRUST-AF PCI confirmed that an edoxaban-based dual antithrombotic strategy is a safe and effective alternative to VKA-based triple therapy for patients with atrial fibrillation undergoing PCI. By successfully dropping aspirin early, this trial reinforced the clinical paradigm shift established by other NOAC trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS) toward adopting NOAC-based dual therapy to minimize excessive bleeding risk while preserving protection against thromboembolism and stent thrombosis.
Historical Context
Historically, patients with atrial fibrillation requiring PCI presented a clinical dilemma: they needed oral anticoagulation (VKA) for stroke prevention and dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) to prevent stent thrombosis. This 'triple therapy' strategy was notoriously associated with unacceptably high rates of major, sometimes fatal, bleeding. In the late 2010s, a series of landmark trials utilizing direct oral anticoagulants (NOACs) sought to investigate whether dropping aspirin and using a NOAC plus a single P2Y12 inhibitor could reduce bleeding without increasing ischemic risk. Following successful trials with rivaroxaban, dabigatran, and apixaban, ENTRUST-AF PCI was the fourth and final major trial that 'closed the loop' by demonstrating the safety and non-inferiority of edoxaban in this high-risk population.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of edoxaban differ from that of a vitamin K antagonist (VKA) like warfarin, and why might this difference theoretically lead to a lower risk of intracranial hemorrhage?
Key Response
Edoxaban is a direct, reversible inhibitor of Factor Xa, specifically targeting one point in the coagulation cascade. VKAs inhibit the synthesis of multiple vitamin K-dependent clotting factors (II, VII, IX, X). The broader disruption of coagulation by VKAs, particularly the profound depletion of Factor VII, is thought to contribute to their higher risk of intracranial hemorrhage compared to target-specific DOACs like edoxaban.
When managing a patient with atrial fibrillation who recently underwent PCI, what are the components of 'triple therapy,' and based on the ENTRUST-AF PCI trial, how does dropping aspirin to form a 'dual therapy' regimen affect the balance between bleeding and ischemic risks?
Key Response
Triple therapy consists of an oral anticoagulant, aspirin, and a P2Y12 inhibitor. ENTRUST-AF PCI demonstrated that early withdrawal of aspirin to use dual therapy (edoxaban plus a P2Y12 inhibitor) significantly reduces bleeding risk without an unacceptable increase in stent thrombosis or ischemic stroke, supporting a shift to shorter durations of triple therapy.
In the ENTRUST-AF PCI trial, there was a numerically higher rate of ischemic events in the edoxaban dual-therapy arm early on. How should this temporal trend influence your decision on the precise timing of aspirin withdrawal for a patient with high anatomical complexity (e.g., left main bifurcation stenting)?
Key Response
While overall ischemic events were similar, trials investigating early aspirin dropping sometimes show an early, small excess in stent thrombosis within the first 30 days. For highly complex PCI where stent thrombosis could be catastrophic, a brief course of triple therapy (up to 1 month) is often preferred before transitioning to dual therapy, balancing early high ischemic risk against cumulative bleeding risk.
ENTRUST-AF PCI is the fourth major trial to evaluate DOAC-based dual therapy in AF patients post-PCI. Looking at the class-effect data across all four trials, how does this consolidated evidence base change our threshold for prescribing triple therapy, and in what rare clinical scenario would you still insist on VKA-based triple therapy?
Key Response
The consistent class effect establishes DOAC plus a P2Y12 inhibitor as the default strategy to mitigate major bleeding. However, VKA-based triple therapy remains indicated in specific scenarios where DOACs are contraindicated, such as patients with mechanical heart valves, moderate-to-severe mitral stenosis, or antiphospholipid syndrome, highlighting the need for individualized application.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ENTRUST-AF PCI trial utilized a non-inferiority design for its primary safety endpoint of major or clinically relevant non-major bleeding. What are the methodological risks of using a non-inferiority margin for safety endpoints in open-label trials, and how might the selection of the specific non-inferiority margin (hazard ratio of 1.20) influence the interpretation of the trial results?
Key Response
In open-label trials, reporting bias for softer endpoints can skew event rates. A non-inferiority margin of 1.20 means the trial could technically declare non-inferiority even if the edoxaban arm had up to 20 percent more bleeding events. Critically appraising this margin ensures we do not accept a clinically meaningful increase in harm, requiring close inspection of absolute event rates and confidence intervals.
As a reviewer assessing the ENTRUST-AF PCI manuscript, you note that the primary endpoint is a composite of ISTH major and clinically relevant non-major (CRNM) bleeding, and the study is open-label. How does the inclusion of CRNM bleeding in an open-label design threaten the internal validity of the safety outcome, and what sensitivity analyses would you request?
Key Response
Open-label designs are highly susceptible to detection bias, especially for subjective outcomes like CRNM bleeding. Investigators or patients knowing their treatment arm might alter their reporting threshold for minor bleeds. A rigorous reviewer would request a sensitivity analysis restricted only to strictly defined, objective ISTH major bleeding or fatal bleeding to confirm the outcome is not driven solely by reporting bias.
Based on the aggregate data from ENTRUST-AF PCI and its sister trials, how should current guidelines update the Class of Recommendation and Level of Evidence for the default antithrombotic strategy in patients with AF undergoing PCI, specifically regarding the duration of aspirin therapy?
Key Response
Current ESC and ACC/AHA guidelines have shifted to recommend DOAC-based dual therapy as the default strategy (Class I or IIa, Level A) for most AF patients post-PCI, limiting aspirin to the peri-procedural period or up to 1 month for high ischemic risk. ENTRUST-AF PCI provides the final piece of the DOAC puzzle, reinforcing Level A evidence that early withdrawal of aspirin significantly reduces bleeding without an unacceptable trade-off in ischemia.
Clinical Landscape
Noteworthy Related Trials
PIONEER AF-PCI
Tested
Rivaroxaban plus P2Y12 inhibitor
Population
Patients with nonvalvular atrial fibrillation undergoing PCI
Comparator
VKA plus dual antiplatelet therapy
Endpoint
Clinically significant bleeding
RE-DUAL PCI
Tested
Dabigatran plus a P2Y12 inhibitor
Population
Patients with atrial fibrillation who had undergone PCI
Comparator
VKA plus dual antiplatelet therapy
Endpoint
ISTH major or clinically relevant nonmajor bleeding
AUGUSTUS
Tested
Apixaban versus VKA and aspirin versus placebo in a 2x2 factorial design
Population
Patients with atrial fibrillation and a recent ACS or undergoing PCI
Comparator
VKA and placebo
Endpoint
ISTH major or clinically relevant nonmajor bleeding
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis